Sur­prise da­ta drop by con­fer­ence puts Arv­inas in cleanup mode

The ear­ly re­lease of a study of Arv­inas’ breast can­cer drug ARV-471 has put the com­pa­ny on de­fense af­ter an aca­d­e­m­ic con­fer­ence put out the da­ta by ac­ci­dent.

On Mon­day, the San An­to­nio Breast Can­cer Sym­po­sium re­leased the full pre­sen­ta­tion for the com­pa­ny’s Phase II tri­al of the drug, which is part of a col­lab­o­ra­tion deal with Pfiz­er that could be worth as much as $2.4 bil­lion.

The study wasn’t sup­posed to be re­leased un­til Dec. 8, Arv­inas said in a press re­lease Tues­day, but the med­ical con­fer­ence “in­cor­rect­ly pub­lished the ab­stract, omit­ting a key safe­ty da­ta ta­ble, and in­ad­ver­tent­ly re­leased the cor­re­spond­ing full da­ta pre­sen­ta­tion on the SABCS web­site.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER